CGRP (8-37) (mouse, rat) (trifluoroacetate salt) (Synonyms: Calcitonin Gene-Related Peptide (8-37), CGRP8-37, VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2) |
カタログ番号GC52438
One-Click Copy Product Info
|
CGRP受容体拮抗剤
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Calcitonin gene-related protein (CGRP) (8-37) is a CGRP receptor antagonist.1 It corresponds to amino acids 8-37 of rodent α-CGRP , a neuropeptide. CGRP (8-37) selectively binds to heterotrimeric complexes of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1) or RAMP3 (IC50s = 1 and 6.2 nM, respectively) over a complex of CRLR and RAMP2 (IC50 = 219 nM). It prevents CGRP-induced increases in heart rate and decreases in blood pressure in transgenic mice expressing rat CRLR in smooth muscle-containing tissues and sympathetic ganglia when administered at a dose of 2 µmol/kg.2 CGRP (8-37) also inhibits p-phenylquinone-induced writhing (ED50 = 6 µg/animal) and decreases body temperature in a dose-dependent manner in mice.3
1.Husmann, K., Born, W., Fischer, J.A., et al.Three receptor-activity-modifying proteins define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse calcitonin-like receptor in COS-7 cellsBiochem. Pharmacol.66(11)2107-2115(2003) 2.Kunz, T.H., Scott, M., Ittner, L.M., et al.Calcitonin gene-related peptide-evoked sustained tachycardia in calcitonin receptor-like receptor transgenic mice is mediated by sympathetic activityAm. J. Physiol. Heart Circ. Physiol.293(4)H2155-H2160(2007) 3.Saxen, M.A., Smith, F.L., Dunlow, L.D., et al.The hypothermic and antinociceptive effects of intrathecal injection of CGRP (8-37) in miceLife Sci.55(21)1665-1674(1994)
| Cas No. | SDF | ||
| 同義語 | Calcitonin Gene-Related Peptide (8-37), CGRP8-37, VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2 | ||
| Canonical SMILES | OC(C(F)(F)F)=O.CC(C)[C@H](N[H])C(N[C@]([C@H](O)C)([H])C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN[H])C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C(C)C)C(N2CCC[C@H]2C(N[C@]([C@H](O)C)([H])C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N)=O)CC3=CC=CC=C3)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)CC(C)C)=O)=O)C)=O)CC(C)C)=O)=O)=O)=O | ||
| Formula | C138H224N42O41 ? XCF3COOH | M.Wt | 3127.5 |
| 溶解度 | PBS (pH 7.2): 2 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 319.7 μL | 1.5987 mL | 3.1974 mL |
| 5 mM | 63.9 μL | 319.7 μL | 639.5 μL |
| 10 mM | 32 μL | 159.9 μL | 319.7 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)